Literature DB >> 7478523

Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET.

S M Myers1, C Eng, B A Ponder, L M Mulligan.   

Abstract

The RET proto-oncogene, which encodes a receptor tyrosine kinase, displays multiple alternative splicing variants. Splicing of sequences 3' of exon 19 to generate several coding and untranslated region (UTR) sequences has been previously reported. We have sequenced the full length RET coding region and characterized the transcripts and 3' UTRs generated by alternative splicing of the RET 3' terminus. These analyses were performed using both RET cDNA cloned from a pheochromocytoma library and reverse transcriptase PCR products generated using RNA from a neuroblastoma cell line (LA-N-2). Three different carboxyl termini were identified. In addition to the nine and 51 terminal amino acid forms already known, we identified a third with 43 terminal amino acids predicted to encode a novel RET protein isoform. A total of 3621 base pairs of DNA 3' of exon 19, which spans the alternatively spliced exons and RET UTRs, was sequenced. Four polyadenylation sites were identified. The observed combinations of polyadenylation sites and 3' coding sequence suggest that RET transcripts with up to 10 different 3' sequences and up to 40 different full length RET transcripts may exist.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478523

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus.

Authors:  S Bolk; A Pelet; R M Hofstra; M Angrist; R Salomon; D Croaker; C H Buys; S Lyonnet; A Chakravarti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 2.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 3.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 4.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 5.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

6.  RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma.

Authors:  Eric Y Lian; Brandy D Hyndman; Serisha Moodley; Sarah M Maritan; Lois M Mulligan
Journal:  Oncogene       Date:  2020-09-03       Impact factor: 9.867

7.  Identification of mutations in two major mRNA isoforms of the Chediak-Higashi syndrome gene in human and mouse.

Authors:  M D Barbosa; F J Barrat; V T Tchernev; Q A Nguyen; V S Mishra; S D Colman; E Pastural; R Dufourcq-Lagelouse; A Fischer; R F Holcombe; M R Wallace; S J Brandt; G de Saint Basile; S F Kingsmore
Journal:  Hum Mol Genet       Date:  1997-07       Impact factor: 6.150

Review 8.  Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx.

Authors:  O Gimm
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 9.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

10.  The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.

Authors:  John J Haddad
Journal:  Saudi Pharm J       Date:  2011-09-23       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.